Advances in pharmacological studies of NF-κB involved in the regulation of nonalcoholic fatty liver disease

Corresponding author: NIU Xiao Shan, 470097414@qq.com

DOI: 10.12201/bmr.202410.00006

•  

  Abstract: Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic disease and one of the common causes of chronic liver disease in China. Its pathogenesis is complex and varied, and it may be affected by multiple influences of insulin resistance, endogenous damaging factors, genetic factors, oxidative stress, intestinal flora imbalance and environmental and dietary factors. NF-κB has important molecular links between metabolic, oxidative, immune and inflammatory responses and is highly activated in NAFLD patients and NAFLD animal models. Drug studies related to NF-κB transcription factors have received increasing attention in recent years, so this article focuses on the mechanism of action of currently promising therapeutic drugs for NAFLD from the perspective of existing NAFLD-related drug studies and whether NF-κB is involved in modulating the effects of such drugs on the development of NAFLD. In current drug studies, vitamin E, pioglitazone, atorvastatin, and some traditional Chinese herbs are expected to be therapeutic drugs for NAFLD, and NF-κB may play an important role in them. However, most of the current drug treatment mechanisms for NAFLD remain on the surface, and some of the drugs are only in the theoretical stage, lacking a large amount of clinical data to support. In the future, we can further explore the mechanism of NF-κB in the pathogenesis of NAFLD as well as the related gene regulatory sites, so as to provide the potential of prevention and treatment for individuals against NAFLD.

  Key words: Non-alcoholic Fatty Liver Disease；NF-kappa B；Inflammation；Insulin Resistance；Drugs, Chinese Herbal

  Submit time: 5 October 2024

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• JIA Chen, GONG Yan, HAN Yijing, JIANG Jianan, LIU Weizheng, ZHANG Daxu, LU Wenping. Correlation between psychological stress and metabolic-associated fatty liver disease. 2022. doi: 10.12201/bmr.202204.00003

  Ming-Dou Du. Study on the causal relationship between physical activity and insulin sensitivity. 2022. doi: 10.12201/bmr.202210.00027

  shen pei cheng. Overview of TCM non-drug therapy of chronic kidney disease. 2024. doi: 10.12201/bmr.202409.00054

  He Fei. Application of preserving stomach qi in differentiating and treating non-tuberculous Mycobacterium lung disease in traditional Chinese medicine. 2024. doi: 10.12201/bmr.202407.00002

  LIU Mi-mi, DU Guo-xia, ZHOU Yi, WU Bin, WU Xiao-ying. Construction and preliminary application of liver cirrhosis special disease database. 2021. doi: 10.12201/bmr.202104.00014

  YANG Xiaodong. Research Progress of PHLDA3 in Diseases. 2024. doi: 10.12201/bmr.202407.00029

  Liu Yanan, Zhan Ming, Han Fei. Research Progress and Prospects of Finerenone in the Treatment of Diabetic Nephropathy. 2024. doi: 10.12201/bmr.202410.00033

  yangyang. Research Progress on Autophagy-Dependent Ferroptosis in Cancer. 2024. doi: 10.12201/bmr.202410.00029

  guoxiaochen, wangpengfei, chenxiu, wuxinyao, zouchunpengchun, 徐茂晟. The value of SWE in early liver and kidney fibrosis in MAFLD. 2024. doi: 10.12201/bmr.202409.00010

  TAN Fei-tong, PAN Tang-xin, Xing Dong, XIAO Ru-yan, HOU Juan, JIA Wei. The impact and mechanisms of Ganoderma lucidum polysaccharide on ETEC-induced enteritis. 2024. doi: 10.12201/bmr.202410.00010

• ID	Submit time	Number	Download
  1	2024-08-29	bmr.202410.00006V1	Download

• Public  Anonymous  To author only Submit Comments